First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing ...
Regeneron (REGN) announced that the FDA has approved Eylea HD Injection 8 mg for the treatment of patients with macular edema following retinal ...
Investing.com -- Regeneron Pharmaceuticals (NASDAQ:REGN) stock rose 3% after the FDA approved its EYLEA HD injection for treating macular edema following retinal vein occlusion (RVO) with up to every ...
DelveInsight's KLKB1 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...
According to the Indonesian Health Survey, nearly 65 million people in Indonesia are suspected of having diabetes mellitus.
The approval is for Eylea to treat macular edema following retinal vein occlusion with up to every eight-week dosing after an initial dosing period. The FDA also approved a monthly dosing option for ...
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics ...
Detailed price information for Kalaris Therapeutics Inc (KLRS-Q) from The Globe and Mail including charting and trades.
Menlo Park resident Carmen Caricchio is on a quest to cure childhood inherited retinal diseases, a group of rare conditions that cause the degeneration of the retina and can lead to vision impairment ...
Panelists discuss how evolving policy reforms will reshape oncology research by balancing innovation, access, and ...
Panelists discuss how increasing utilization management oversight affects physician autonomy and the shared decision-making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback